Gainers
- Venus Concept (NASDAQ:VERO) shares rose 129.5% to $6.61 during Tuesday's after-market session. The market value of their outstanding shares is at $4.3 million.
 - SCWorx (NASDAQ:WORX) shares moved upwards by 60.8% to $1.28. The market value of their outstanding shares is at $2.6 million.
 - Salarius Pharmaceuticals (NASDAQ:SLRX) shares increased by 34.26% to $1.09. The company's market cap stands at $1.8 million.
 - NAYA Biosciences (NASDAQ:NAYA) shares moved upwards by 13.98% to $2.2. The market value of their outstanding shares is at $10.8 million.
 - Aethlon Medical (NASDAQ:AEMD) stock moved upwards by 12.12% to $0.37. The company's market cap stands at $7.6 million.
 - Anixa Biosciences (NASDAQ:ANIX) shares moved upwards by 10.88% to $2.63. The market value of their outstanding shares is at $84.6 million.
 
Losers
- Vincerx Pharma (NASDAQ:VINC) stock declined by 55.6% to $0.24 during Tuesday's after-market session.
 - NanoVibronix (NASDAQ:NAOV) shares declined by 14.31% to $6.11. The market value of their outstanding shares is at $4.6 million.
 - Protagenic Therapeutics (NASDAQ:PTIX) shares fell 12.69% to $0.24. The company's market cap stands at $1.8 million.
 - 180 Life Sciences (NASDAQ:ATNF) stock declined by 12.26% to $0.62. The market value of their outstanding shares is at $2.4 million.
 - Revelation Biosciences (NASDAQ:REVB) stock declined by 11.39% to $3.27. The company's market cap stands at $2.9 million.
 - ABVC BioPharma (NASDAQ:ABVC) stock decreased by 8.36% to $0.82. The company's market cap stands at $19.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
 
This article was generated by Benzinga's automated content engine and reviewed by an editor.
AEMDAethlon Medical Inc
$5.20-1.14%
ANIXAnixa Biosciences Inc
$3.88-6.17%
NAOVNanoVibronix Inc
$5.14-%
PTIXProtagenic Therapeutics Inc
$2.14-16.7%
REVBRevelation Biosciences Inc
$1.293.05%
SLRXSalarius Pharmaceuticals Inc
$3.81-2.06%
VEROVenus Concept Inc
$2.13-0.23%
VINCVincerx Pharma Inc
$0.00530-94.7%
WORXSCWorx Corp
$0.31001.51%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
